Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RLAY 
Relay Therapeutics Inc (RLAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: RLAY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.9
1 Year Target Price $13.9
| 6 | Strong Buy |
| 5 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.43% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 615.49M USD | Price to earnings Ratio - | 1Y Target Price 13.9 |
Price to earnings Ratio - | 1Y Target Price 13.9 | ||
Volume (30-day avg) 13 | Beta 1.59 | 52 Weeks Range 1.77 - 10.72 | Updated Date 07/9/2025 |
52 Weeks Range 1.77 - 10.72 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1105.21% |
Management Effectiveness
Return on Assets (TTM) -28.82% | Return on Equity (TTM) -45.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -47708573 | Price to Sales(TTM) 80.15 |
Enterprise Value -47708573 | Price to Sales(TTM) 80.15 | ||
Enterprise Value to Revenue 18.17 | Enterprise Value to EBITDA -0.8 | Shares Outstanding 171444992 | Shares Floating 110060810 |
Shares Outstanding 171444992 | Shares Floating 110060810 | ||
Percent Insiders 1.51 | Percent Institutions 105.9 |
Upturn AI SWOT
Relay Therapeutics Inc
Company Overview
History and Background
Relay Therapeutics, founded in 2016, is a clinical-stage precision medicine company transforming the drug discovery process by combining insights in protein motion with advanced experimental and computational approaches.
Core Business Areas
- Discovery and Development of Targeted Therapies: Focuses on developing novel therapeutics for oncology and genetic diseases by leveraging protein motion to discover and design drugs that bind to previously undruggable targets.
Leadership and Structure
The leadership team includes Sanjiv Patel (President and CEO). The organizational structure is typical of a biotech company, with research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- RLY-4008 (FGFR2 inhibitor): A highly selective FGFR2 inhibitor designed to overcome resistance mutations. Currently in clinical development for cholangiocarcinoma and other FGFR2-altered cancers. Market share data is not yet available. Competitors include Incyte (PEMAZYRE) and QED Therapeutics.
- RLY-2608 (PI3Ku03b1 inhibitor): An allosteric PI3Ku03b1 inhibitor. Currently in clinical trials. Market share data is not yet available. Competitors include Novartis (Piqray).
Market Dynamics
Industry Overview
The oncology drug market is large and competitive, with increasing focus on precision medicine and targeted therapies.
Positioning
Relay Therapeutics is positioned as a leader in developing precision medicines targeting protein motion, giving it a competitive edge in addressing previously undruggable targets.
Total Addressable Market (TAM)
The total addressable market for oncology drugs is estimated to be in the hundreds of billions of dollars. Relay Therapeutics is positioned to capture a portion of this market with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform
- Strong scientific team
- Focus on challenging drug targets
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on clinical trial outcomes
Opportunities
- Potential for breakthrough therapies
- Partnerships with larger pharmaceutical companies
- Expansion into new disease areas
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- INCY
- NVS
Competitive Landscape
Relay Therapeutics' advantage lies in its proprietary platform. Disadvantages include being a smaller company with limited resources compared to established players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by advancement of drug candidates through clinical trials and expansion of the pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing RLY-4008 and RLY-2608 into later-stage clinical trials and expanding the drug discovery pipeline.
Summary
Relay Therapeutics is a promising clinical-stage biotech with a novel drug discovery platform. Its success hinges on the success of its clinical trials. Its main challenges are typical of a biotech company: clinical trial risks, high cash burn, and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Relay Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-07-16 | CEO, President & Director Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | ||
Sector Healthcare | Industry Biotechnology | Full time employees 259 | Website https://www.relaytx.com |
Full time employees 259 | Website https://www.relaytx.com | ||
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.